Overview

PEN-866 in Patients With Advanced Solid Malignancies

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Tarveda Therapeutics
Treatments:
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Niraparib